Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Immunome (Nasdaq: IMNM), a biotechnology company specializing in targeted cancer therapies, has announced inducement grants under Nasdaq Listing Rule 5635(c)(4). The company's Compensation Committee approved non-statutory stock options for 49,000 shares of common stock to four new employees under its 2024 Inducement Plan.
The stock options were granted on March 3, 2025, with an exercise price of $8.94 per share, matching the company's closing price on that date. The options will vest over four years, with 25% vesting after one year and the remaining balance vesting monthly over 36 months, contingent on continued employment.
Immunome (Nasdaq: IMNM), un'azienda biotecnologica specializzata in terapie mirate per il cancro, ha annunciato concessioni di incentivazione ai sensi della Regola di quotazione Nasdaq 5635(c)(4). Il Comitato per la Compensazione della società ha approvato opzioni su azioni non statutarie per 49.000 azioni ordinarie a favore di quattro nuovi dipendenti nell'ambito del Piano di Incentivazione 2024.
Le opzioni su azioni sono state concesse il 3 marzo 2025, con un prezzo di esercizio di $8,94 per azione, corrispondente al prezzo di chiusura della società in quella data. Le opzioni matureranno in quattro anni, con il 25% che matura dopo un anno e il saldo restante che matura mensilmente per 36 mesi, a condizione di continuare l'impiego.
Immunome (Nasdaq: IMNM), una compañía biotecnológica especializada en terapias contra el cáncer dirigidas, ha anunciado concesiones de inducción bajo la Regla de Cotización Nasdaq 5635(c)(4). El Comité de Compensación de la compañía aprobó opciones sobre acciones no estatutarias para 49,000 acciones comunes para cuatro nuevos empleados bajo su Plan de Inducción 2024.
Las opciones sobre acciones fueron otorgadas el 3 de marzo de 2025, con un precio de ejercicio de $8.94 por acción, coincidiendo con el precio de cierre de la compañía en esa fecha. Las opciones se consolidarán durante cuatro años, con el 25% consolidándose después de un año y el saldo restante consolidándose mensualmente durante 36 meses, condicionado a la continuidad del empleo.
Immunome (Nasdaq: IMNM), 암 치료에 특화된 생명공학 회사가 Nasdaq 상장 규정 5635(c)(4)에 따라 유인 보상을 발표했습니다. 회사의 보상위원회는 2024 유인 계획에 따라 네 명의 신입 직원에게 49,000주의 보통주에 대한 비상장 주식 옵션을 승인했습니다.
주식 옵션은 2025년 3월 3일에 부여되었으며, 주당 행사 가격은 $8.94로, 해당 날짜의 회사 종가와 일치합니다. 옵션은 4년에 걸쳐 만료되며, 1년 후 25%가 만료되고 나머지 잔액은 36개월 동안 매달 만료되며, 계속 고용되는 조건입니다.
Immunome (Nasdaq: IMNM), une entreprise biotechnologique spécialisée dans les thérapies ciblées contre le cancer, a annoncé des concessions d'incitation conformément à la règle de cotation Nasdaq 5635(c)(4). Le comité de rémunération de l'entreprise a approuvé des options d'achat d'actions non statutaires pour 49 000 actions ordinaires en faveur de quatre nouveaux employés dans le cadre de son Plan d'incitation 2024.
Les options d'achat d'actions ont été accordées le 3 mars 2025, avec un prix d'exercice de 8,94 $ par action, correspondant au prix de clôture de l'entreprise à cette date. Les options seront acquises sur quatre ans, avec 25 % acquises après un an et le solde restant acquis mensuellement pendant 36 mois, sous réserve de maintien de l'emploi.
Immunome (Nasdaq: IMNM), ein biotechnologisches Unternehmen, das sich auf gezielte Krebstherapien spezialisiert hat, hat Anreizvergaben gemäß der Nasdaq-Listing-Regel 5635(c)(4) angekündigt. Der Vergütungsausschuss des Unternehmens genehmigte nicht-statutäre Aktienoptionen für 49.000 Aktien des Stammkapitals für vier neue Mitarbeiter im Rahmen seines Anreizplans 2024.
Die Aktienoptionen wurden am 3. März 2025 gewährt, mit einem Ausübungspreis von 8,94 $ pro Aktie, der dem Schlusskurs des Unternehmens an diesem Tag entspricht. Die Optionen werden über vier Jahre fällig, wobei 25 % nach einem Jahr fällig werden und der verbleibende Betrag monatlich über 36 Monate fällig wird, vorbehaltlich einer fortgesetzten Beschäftigung.
- Successful recruitment of 4 new employees indicating company growth
- Implementation of employee retention strategy through stock options
- Potential future dilution from 49,000 new stock options
Each stock option has an exercise price per share equal to
About Immunome
Immunome is a clinical-stage targeted oncology company committed to developing first-in-class and best-in-class targeted therapies designed to improve outcomes for cancer patients. We are advancing an innovative portfolio of therapeutics, drawing on leadership that previously played key roles in the design, development, and commercialization of cutting-edge targeted cancer therapies, including antibody-drug conjugate therapies (ADCs). Our most advanced pipeline programs are varegacestat (formerly AL102), a gamma secretase inhibitor which is currently in a Phase 3 trial for treatment of desmoid tumors, IM-1021, a ROR1 ADC with an active IND, and IM-3050, a FAP-targeted radioligand, which is the subject of an IND expected to be submitted in the first quarter of 2025. Our pipeline also includes IM-1617, IM-1335, and IM-1340, all of which are preclinical ADCs pursuing undisclosed targets with expression in multiple solid tumors. For more information, visit www.immunome.com.
Cautionary Statement Regarding Forward-Looking Statements
Statements in this press release that are not purely historical in nature are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include Immunome’s expectations regarding progress of its pipeline and timeline for regulatory filings, and other statements regarding forecasts for the future. These forward-looking statements are based on Immunome’s current expectations and involve assumptions that may never materialize or may prove to be incorrect; consequently, actual results may differ materially from those expressed or implied in the statements due to a number of factors, including, but not limited to, the risks and uncertainties described in Immunome’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2024, filed with the SEC on November 13, 2024, and in Immunome’s other filings with the SEC. Except as required by law, Immunome assumes no obligation and does not intend to update any forward-looking statements included in this press release.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250306075046/en/
Investor Contact
Max Rosett
Chief Financial Officer
investors@immunome.com
Source: Immunome, Inc.
FAQ
What is the exercise price for Immunome's (IMNM) new stock options granted on March 3, 2025?
How many shares of common stock are included in Immunome's (IMNM) March 2025 inducement grants?
What is the vesting schedule for Immunome's (IMNM) March 2025 stock option grants?
How many employees received Immunome's (IMNM) March 2025 inducement stock options?
